MicroRNA as a potential biomarker for kidney cancer
Recently, researchers are focusing on microRNAs (miRNAs) circulating in the [...]
Current treatment of advanced papillary renal cell carcinoma
Despite significant improvements in the treatment outcomes of clear cell [...]
UK cancer survival rates lag behind other European countries
A recent study, commissioned by the Association of the British Pharmaceutical [...]
Recommendations for the management of rare kidney cancers
Patients diagnosed with a rare kidney cancer are often treated [...]
National Cancer Patient Experience Survey show patients are increasingly positive about their NHS cancer care
The annual National Cancer Patient Experience Survey (NCPES) published today [...]
Type of long-term response to targeted therapy affects outcomes for advanced kidney cancer
A retrospective study conducted by researchers in the Czech Republic [...]
NHS comes out on top in a review of international healthcare systems
Here is some good news about the UK NHS: In [...]
Initiation of a phase III trial of immunotherapy plus targeted therapy combinations versus sunitinib
Exelixis and Bristol-Myers Squibb have announced that they have initiated [...]
Cabozantinib recommended by NICE for second-line treatment of advanced kidney cancer
Today, the National Institute for Health and Care Excellence (NICE), [...]
Alternative scheduling of sunitinib and new treatment for kidney cancer: ASCO 2017 update
The following video from Practice Update is an interview with [...]
